Edgar Filing: MedaSorb Technologies CORP - Form 8-K

MedaSorb Technologies CORP Form 8-K February 15, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 8, 2007

MEDASORB TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter)

Nevada000-5103898-0373793(State or other jurisdiction
of incorporation)(Commission
File Number)(I.R.S. Employer
Identification Number)

7 Deer Park Drive, Suite K, Monmouth Junction, New Jersey 08852 (Address of principal executive office) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13c-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

On February 8, 2007, our Board of Directors approved the grant to Al Kraus, our President and Chief Executive Officer, of an immediately exercisable option to purchase 400,000 shares of our common stock at an exercise price of \$1.26 (the closing price of our common stock on the date of grant).

2

Edgar Filing: MedaSorb Technologies CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 14, 2007

MEDASORB TECHNOLOGIES CORPORATION

By: /s/ David Lamadrid

David Lamadrid, Chief Financial Officer

3